NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
53 trialsNCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT01711554 2026-04-13
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03786783 2026-04-13
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00026312 2026-03-05
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT06942039 2026-02-27
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
C17 Council
Phase EARLY_PHASE1 Recruiting
NCT01175356 2026-01-23
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Phase 1 Completed
NCT04385277 2025-10-27
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 2 Active not recruiting
NCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00392327 2025-06-13
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Children's Oncology Group
Phase 3 Active not recruiting
NCT00555399 2024-08-22
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT01526603 2024-02-26
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT06047535 2023-09-21
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
SciClone Pharmaceuticals
Phase 4 Not yet recruiting
NCT02641782 2022-11-04
NB2013-HR
University of Cologne
Phase 2 Terminated
NCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT00567567 2022-04-28
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00867178 2022-01-13
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
National Cancer Institute (NCI)
Phase 1 Completed
NCT03291080 2021-10-19
My-CRA
Nova Laboratories Limited
Phase 1/2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00528437 2021-07-08
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Phase 2 Completed
NCT00499616 2021-07-06
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT01701479 2020-07-14
LTI
St. Anna Kinderkrebsforschung
Phase 1/2 Unknown
NCT02100930 2020-02-28
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01183884 2019-11-14
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01334515 2019-10-21
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT01183416 2019-10-09
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01183429 2019-08-13
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01103375 2018-08-01
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Wake Forest University Health Sciences
Phase 1 Terminated
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn
NCT02771743 2016-05-24
Response-based Treatment of High-risk Neuroblastoma
Samsung Medical Center
Phase 2 Unknown
NCT01208454 2015-11-24
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT00526318 2015-07-16
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase NA Unknown
NCT00078988 2015-05-07
High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
Children's Oncology Group
Phase 3 Completed
NCT00030719 2014-06-24
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00217412 2014-06-17
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00017368 2014-02-13
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00070200 2014-02-13
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT01319838 2013-12-10
Aflac ST1001
Emory University
Phase 1 Withdrawn
NCT00004110 2013-10-31
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00939965 2013-08-12
Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase NA Unknown
NCT00410631 2013-08-07
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00004188 2013-05-17
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00969722 2013-03-08
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
United Therapeutics
Phase 2 Terminated
NCT00040872 2013-03-07
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00089258 2013-01-17
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005576 2013-01-16
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed